GMAB Relative Valuation
GMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GMAB is overvalued; if below, it's undervalued.
Historical Valuation
Genmab A/S (GMAB) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.85 is considered Undervalued compared with the five-year average of 45.82. The fair price of Genmab A/S (GMAB) is between 23.18 to 99.54 according to relative valuation methord. Compared to the current price of 21.40 USD , Genmab A/S is Undervalued By 7.69%.
Relative Value
Fair Zone
23.18-99.54
Current Price：21.40
7.69%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.58
P/B
Median3y
4.65
Median5y
5.95
8.62
FCF Yield
Median3y
4.56
Median5y
3.71
Competitors Valuation Multiple
The average P/S ratio for GMAB's competitors is 3.40, providing a benchmark for relative valuation. Genmab A/S Corp (GMAB) exhibits a P/S ratio of 3.53, which is 3.60% above the industry average. Given its robust revenue growth of 18.57%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Genmab A/S (GMAB) currently overvalued or undervalued?
What is Genmab A/S (GMAB) fair value?
How does GMAB's valuation metrics compare to the industry average?
What is the current P/B ratio for Genmab A/S (GMAB) as of Jul 13 2025?
What is the current FCF Yield for Genmab A/S (GMAB) as of Jul 13 2025?
What is the current Forward P/E ratio for Genmab A/S (GMAB) as of Jul 13 2025?